<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03043846</url>
  </required_header>
  <id_info>
    <org_study_id>2016-A00564-47</org_study_id>
    <nct_id>NCT03043846</nct_id>
  </id_info>
  <brief_title>Treat to Target Trial in Axial Spondylo Arthritis : The TICOSPA (Tight Control in Spondyloarthritis)</brief_title>
  <acronym>TICOSPA</acronym>
  <official_title>Treat to Target Trial in Axial Spondylo Arthritis : The TICOSPA (Tight Control in Spondyloarthritis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association de Recherche Clinique en Rhumatologie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>RCTs</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Association de Recherche Clinique en Rhumatologie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a not interventional, pragmatic, prospective, randomized (cluster) study to evaluate
      the potential benefit of a Treat to Target approach in comparison to routine treatment (i.e.
      usual care) in patients with axial spondyloarthritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is reflecting the usual care either in accordance to the treating rheumatologist
      (arm: usual care) or in accordance to the international scientific recommendations (arm: T2T)

      The tight control means that as soon as a treatment is initiated in a patient, the time
      permitting to evaluate its potential efficacy/safety has to be determined. In terms of
      safety, such time frame can be very short based on the occurrence of adverse events. In terms
      of efficacy it is usually recommended to evaluate an NSAIDs after 2 to 4 weeks of treatment
      intake and the TNF blockers after 12 to 16 weeks.

      The Treat to Target means that there is an a priori decision of the target to reach while
      initiating a treatment and more importantly an a priori decision to intensify the treatment
      in case such target is not achieved.

      There will be 2 arms in the study (tight control and treat to target arm and usual care arm).

      160 patients (80 patients per arm) will be included during one year by 18 centers (10 in
      France, 4 in Belgium and 4 in Netherlands). Patients will be followed during 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2016</start_date>
  <completion_date type="Anticipated">January 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of patients with a significant improvement in the ASAS-HI score after a one year follow-up in the 2 groups.</measure>
    <time_frame>At one year follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percentage of patients reaching an ASDAS clinically important improvement after a one year follow-up in the 2 groups.</measure>
    <time_frame>At one year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of patients reaching a BASDAI 50 after a one year follow-up in the 2 groups.</measure>
    <time_frame>Over one year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the change in the BASDAI over one year follow-up in the 2 groups.</measure>
    <time_frame>Over one year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in the ASAS-NSAID score over one year follow-up in the 2 groups.</measure>
    <time_frame>Over one year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in WPAI results after a one year follow-up in the 2 groups.</measure>
    <time_frame>After a one year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The evolution of EuroQOL after a one year follow-up in the 2 groups.</measure>
    <time_frame>After a one year follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The changes in the self-report questionnaire on health resource utilization after a one year follow-up in the 2 groups.</measure>
    <time_frame>After a one year follow-up</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Axial Spondyloarthritis</condition>
  <arm_group>
    <arm_group_label>Tight control and Treat to Target arm</arm_group_label>
    <description>For this group, the treating rheumatologist will agree to monitor very closely (at least every 4 weeks) and also to treat their patients in accordance with a pre-defined strategy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care arm</arm_group_label>
    <description>For this arm, the treating rheumatologists will continue to manage the enrolled patients in accordance to their usual care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Follow-up every 3 months during 1 year (data collection in eCRF)</intervention_name>
    <arm_group_label>Tight control and Treat to Target arm</arm_group_label>
    <arm_group_label>Usual care arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Follow-up every month to follow the pre-defined strategy</intervention_name>
    <arm_group_label>Tight control and Treat to Target arm</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with a diagnosis of predominant axial spondyloarthritis according to the axial ASAS
        criteria AND the opinion of the treating rheumatologist, and an active disease defined as
        an (ASDAS ≥ 2.1), and non-optimally treated with NSAIDs.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (between 18 and 65 years old)

          -  With a diagnosis of axial spondyloarthritis according to the axial ASAS criteria AND
             the opinion of the treating rheumatologist.

          -  Active disease defined as an ASDAS ≥ 2.1

          -  Predominant axial disease meaning that:

               -  Patients with non-spinal rheumatological symptoms and/or extra-rheumatological
                  manifestations requiring at baseline the initiation of a specific treatment will
                  be excluded.

               -  Patients with a past history and/or a current well controlled non-spinal
                  rheumatological or extra-rheumatological features will be eligible for the study.

          -  Non-optimally treated with NSAIDs (i.e. who have not received at least 2 NSAIDS, daily
             during at least 2 weeks at full dose). Annex III summarizes the list of commonly used
             NSAIDs and the definition of a &quot;full&quot; use.

          -  With available pelvic X-rays, B27 and MRI of the sacro-iliac joints (performed at any
             time since symptoms onset)

          -  With no contraindication to the use of a NSAID

          -  With no intake of apremilast during the previous 3 months

          -  Able to understand the objectives of the study and to fill the questionnaires

          -  Written informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anna MOLTO</last_name>
    <email>anna.molto@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maxime DOUDAGOS</last_name>
    <email>maxime.dougados@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZ GENT</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peggy JACQUES</last_name>
    </contact>
    <investigator>
      <last_name>Peggy JACQUES</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jessa Ziekenhuis</name>
      <address>
        <city>Hasselt</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jan LENAERTS</last_name>
    </contact>
    <investigator>
      <last_name>Jan LENAERTS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reumatologie Medizorg</name>
      <address>
        <city>Merksem</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rik JOOS</last_name>
    </contact>
    <investigator>
      <last_name>Rik JOOS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Alma</name>
      <address>
        <city>Sijsele</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe CARRON</last_name>
    </contact>
    <investigator>
      <last_name>Philippe CARRON</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Gabriel Montpied</name>
      <address>
        <city>Clermont-ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin SOUBRIER</last_name>
    </contact>
    <investigator>
      <last_name>Martin Soubrier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Athan BAILLET</last_name>
    </contact>
    <investigator>
      <last_name>Athan BAILLET</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Le Mans</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuelle DERNIS</last_name>
    </contact>
    <investigator>
      <last_name>Emmanuelle DERNIS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Lapeyronnie</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cédric LUKAS</last_name>
    </contact>
    <investigator>
      <last_name>Cédric LUKAS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ch Mulhouse</name>
      <address>
        <city>Mulhouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laetitia SPARSA</last_name>
    </contact>
    <investigator>
      <last_name>Laetitia SPARSA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Minh NGUYEN</last_name>
    </contact>
    <investigator>
      <last_name>Minh NGUYEN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital de La Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laure GOSSEC</last_name>
    </contact>
    <investigator>
      <last_name>Laure GOSSEC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Mondor</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascal CLAUDEPIERRE</last_name>
    </contact>
    <investigator>
      <last_name>Pascal CLAUDEPIERRE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie POUPLIN</last_name>
    </contact>
    <investigator>
      <last_name>Sophie POUPLIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adeline RUYSSEN-WITRAND</last_name>
    </contact>
    <investigator>
      <last_name>Adeline RUYSSEN-WITRAND</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMCG</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anneke SPOORENBERG</last_name>
    </contact>
    <investigator>
      <last_name>Anneke SPOORENBERG</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zuyderland MC</name>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mirian STARMANS-KOOL</last_name>
    </contact>
    <investigator>
      <last_name>Mirian STARMANS-KOOL</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LUMC</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Floris van GAALEN</last_name>
    </contact>
    <investigator>
      <last_name>Floris van GAALEN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maastricht UMC</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Astrid van TUBERGEN</last_name>
    </contact>
    <investigator>
      <last_name>Astrid van TUBERGEN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2017</study_first_submitted>
  <study_first_submitted_qc>February 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2017</study_first_posted>
  <last_update_submitted>February 3, 2017</last_update_submitted>
  <last_update_submitted_qc>February 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treat to Target approach</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

